+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Sulfonylureas - Global Strategic Business Report

  • PDF Icon

    Report

  • 362 Pages
  • July 2025
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 6110032
The global market for Sulfonylureas was valued at US$9.7 Billion in 2024 and is projected to reach US$10.8 Billion by 2030, growing at a CAGR of 1.8% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Sulfonylureas market.

Global Sulfonylureas Market - Key Trends & Drivers Summarized

Sulfonylureas constitute a class of herbicides widely used to control broadleaf weeds and grasses in cereal crops, rice, vegetables, and turf. Noted for their ultra-low dosage rates - often just grams per hectare - these compounds inhibit ALS (acetolactate synthase), disrupting weed biosynthesis. Recent market evolution reflects a shift towards multiple-resistance weed populations, prompting the development of next-gen sulfonylureas with tailored selectivity, soil persistence, and safety profiles. Formulation improvements, such as micro-encapsulation and nanocarrier delivery, enhance soil targeting while reducing off-target movement.

Regulatory scrutiny over agrochemical residues has driven adoption of sulfonylureas with low-toxicity and rapid degradation pathways. Many agrochemical leaders now offer integrated packaging - combining sulfonylureas with pre-emergent herbicides in controlled-release blends. Digital spraying platforms and variable-rate applicators further improve precision, reducing environmental load while increasing efficacy.

How Are Biochemical and Resistance Challenges Being Tackled?

ultiple-resistance weeds - evolved to withstand several ALS inhibitors - have triggered investment in dual-mode herbicides combining sulfonylureas with unique active ingredients like synthetic auxins. Molecular design now includes functional groups that reduce weed metabolism and elongate treatment windows. Additionally, metabolic profiling and gene-expression analytics guide targeted compound optimization. Soil microbiome studies are enabling scientists to predict compound longevity and impact, ensuring safe use in sensitive regions.

Novel formulations featuring stabilized emulsions and biodegradable surfactants enhance root-zone delivery. These systems persist just enough to provide effective control, then break down swiftly, minimizing groundwater infiltration and meeting environmental standards.

Who Is Adopting These Solutions and Where?

igh-value crop growers in Asia-Pacific - particularly rice farmers in India, China, and Southeast Asia - depend heavily on selective sulfonylureas due to their efficiency and low cost per area. In Europe, integrated weed management programs favor low-dose, targeted use within crop rotation plans aiming to reduce seasonal herbicide volume. North American conservation agriculture systems use strip-tilled pre-emergent blends to maintain no-till systems while tackling persistent grassy weeds.

Emerging economies in Latin America and East Africa are adopting micro-pelletized sulfonylureas distributed via drone sprayers, ensuring uniform coverage and minimizing overlap. Agricultural service platforms now offer herbicide-as-a-service models, where farmers subscribe to scheduled drone or tractor rigs delivering optimized mixes seasonally.

The Growth in the Sulfonylureas Market Is Driven by Several Factors…

he market’s expansion stems from the need to control herbicide-resistant weed populations, driving innovation in dual-mode actives and dosage-efficient blends. Precision ag technologies - drone and GPS-sprayed micro-pellets - expand reach and minimize waste. Regulatory incentives for low-residue, fast-degrading agrochemicals encourage product reformulation. Crop intensification and double cropping practices in Asia increase application frequency. Finally, service-based delivery models reduce barriers to adoption among smallholder farmers in developing regions.

Scope of the Report

The report analyzes the Sulfonylureas market, presented in terms of market value (USD). The analysis covers the key segments and geographic regions outlined below:
  • Segments: Indication (Diabetes Indication, Other Indications); Form (Tablet Form, Capsules Form, Other Forms); End-Use (Hospitals End-Use, Specialty Clinics End-Use, Other End-Uses).
  • Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Diabetes Indication segment, which is expected to reach US$6.4 Billion by 2030 with a CAGR of a 1.2%. The Other Indications segment is also set to grow at 2.6% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, valued at $2.6 Billion in 2024, and China, forecasted to grow at an impressive 3.5% CAGR to reach $2.0 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Sulfonylureas Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Sulfonylureas Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Sulfonylureas Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as Abbott Laboratories, Amgen Inc., AstraZeneca plc, Bayer AG, Biocon Ltd. and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 32 companies featured in this Sulfonylureas market report include:

  • Abbott Laboratories
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Biocon Ltd.
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • GSK (GlaxoSmithKline)
  • Lupin Pharmaceuticals
  • Merck & Co., Inc.
  • Mylan (now part of Viatris)
  • Novartis International AG
  • Pfizer Inc.
  • Roche (Genentech subsidiary)
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Zydus Cadila (Cadila Healthcare)

This edition integrates the latest global trade and economic shifts into comprehensive market analysis. Key updates include:

  • Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
  • Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes historical analysis from 2015 to 2023.
  • Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
  • Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
  • Competitive Intelligence: Updated global market share estimates for 2025 (E), competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
  • Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Sulfonylureas - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Global Diabetes Prevalence Throws the Spotlight Back on Affordable Oral Hypoglycemic Agents
  • Favorable Pricing and Established Safety Profiles Sustain Use of Sulfonylureas in Cost-Constrained Healthcare Systems
  • Generic Competition and Expiry of Patents Expand Access and Volume Sales in Emerging Economies
  • Integration into Combination Therapies Enhances Therapeutic Versatility in Type 2 Diabetes Treatment
  • Clinical Preference for Sulfonylureas in Initiation Therapy Maintains Relevance in Low-Resource Settings
  • Increased Demand for Step-Wise Treatment Protocols Drives Continued Role of Sulfonylureas in Sequential Therapy
  • Global Public Health Programs and WHO Essential Drug Listings Promote Adoption in National Formularies
  • Adoption of Value-Based Care Models Strengthens Business Case for Economical Diabetes Management Solutions
  • Comparative Cost Advantage Over New-Age Antidiabetics Preserves Market Share in Public Sector Institutions
  • Growing Investment in Patient Education and Adherence Support Reaffirms Sulfonylurea Prescriptions
  • Development of Modified-Release Formulations Improves Tolerability and Reduces Hypoglycemia Risk
  • Rising Use of e-Prescriptions and Clinical Decision Tools Supports Rational Sulfonylurea Utilization
  • Ongoing Pharmacovigilance and Real-World Evidence Studies Sustain Clinical Confidence in Legacy Drug Class
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Sulfonylureas Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • Table 2: World Recent Past, Current & Future Analysis for Sulfonylureas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 3: World Historic Review for Sulfonylureas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • Table 4: World 16-Year Perspective for Sulfonylureas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • Table 5: World Recent Past, Current & Future Analysis for Diabetes Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 6: World Historic Review for Diabetes Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • Table 7: World 16-Year Perspective for Diabetes Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • Table 8: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 9: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • Table 10: World 16-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for Tablet Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 12: World Historic Review for Tablet Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • Table 13: World 16-Year Perspective for Tablet Form by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • Table 14: World Recent Past, Current & Future Analysis for Capsules Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 15: World Historic Review for Capsules Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • Table 16: World 16-Year Perspective for Capsules Form by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • Table 17: World Recent Past, Current & Future Analysis for Other Forms by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 18: World Historic Review for Other Forms by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • Table 19: World 16-Year Perspective for Other Forms by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • Table 20: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 21: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • Table 22: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • Table 23: World Recent Past, Current & Future Analysis for Specialty Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 24: World Historic Review for Specialty Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • Table 25: World 16-Year Perspective for Specialty Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • Table 26: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 27: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • Table 28: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Sulfonylureas Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
CANADA
JAPAN
  • Sulfonylureas Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
CHINA
  • Sulfonylureas Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
EUROPE
  • Sulfonylureas Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
FRANCE
  • Sulfonylureas Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
GERMANY
  • Sulfonylureas Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
ITALY
UNITED KINGDOM
  • Sulfonylureas Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
SPAINRUSSIAREST OF EUROPE
ASIA-PACIFIC
  • Sulfonylureas Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
AUSTRALIA
  • Sulfonylureas Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
INDIA
  • Sulfonylureas Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Sulfonylureas Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Sulfonylureas Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Sulfonylureas Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abbott Laboratories
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Biocon Ltd.
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • GSK (GlaxoSmithKline)
  • Lupin Pharmaceuticals
  • Merck & Co., Inc.
  • Mylan (now part of Viatris)
  • Novartis International AG
  • Pfizer Inc.
  • Roche (Genentech subsidiary)
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Zydus Cadila (Cadila Healthcare)

Table Information